censored cwx= [2866,5839) - cmax= [5839,m61] censored [5839, fatigue: of the 80 patients in the...
TRANSCRIPT
![Page 1: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/1.jpg)
![Page 2: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/2.jpg)
![Page 3: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/3.jpg)
![Page 4: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/4.jpg)
![Page 5: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/5.jpg)
![Page 6: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/6.jpg)
![Page 7: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/7.jpg)
(b) (4)
![Page 8: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/8.jpg)
![Page 9: Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during](https://reader030.vdocuments.net/reader030/viewer/2022041021/5ed0aae2fddbef3ff77d7ddb/html5/thumbnails/9.jpg)
31 Page(s) Withheld
______ Trade Secret / Confidential (b4)
_x___ Draft Labeling (b4)
______ Draft Labeling (b5)
______ Deliberative Process (b5)